Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229-3039, USA.
Cephalalgia. 2011 Jun;31(8):897-905. doi: 10.1177/0333102411406755. Epub 2011 May 17.
To evaluate the efficacy of Coenzyme Q10 (CoQ10) supplementation in the prevention of migraine in children using a placebo-controlled, double-blinded, crossover, add-on trial.
CoQ10 has been demonstrated to have efficacy in migraine prevention in adults but lacks pediatric research with more rigorous methodology. CoQ10 has been observed to be deficient in a significant number of children and adolescents presenting to tertiary headache centers. CoQ10 has the potential to modify both the inflammatory changes that occur during recurrent migraine and the alteration of mitochondrial function. A deficit of CoQ10 could thus affect the response to treatment and clinical characteristics of migraine in children and adults.
One-hundred-and-twenty children and adolescents with migraine headache were randomized in a crossover, double-blind, placebo-controlled, randomized, add-on study to receive a placebo or CoQ10 (100 mg) supplement for 224 days. Data for 76 patients were available at the crossover point and 50 were analysed at the endpoint. Response to treatment, overall headache improvement, and headache disability were assessed.
Both the placebo and CoQ10 groups showed reduced migraine frequency [F(1, 60)=15.68, p<0.001], severity [F(1, 54)=8.09, p=0.006], and duration [F(1, 45)=6.27, p=0.016] over time. CoQ10 treated patients had a significantly greater improvement in frequency from subject reported baseline starting within 4 weeks of initiation. No group differences comparing the first 4 weeks of treatment with the last 4 weeks of treatment were found in migraine frequency [F(1, 60)=2.34, p>0.05], severity [F(1, 54)=0.06, p>0.05], or duration [F(1, 45)=0.14, p>0.05].
Overall, results of the study demonstrate that children and adolescents with migraine improved over time with multidisciplinary, standardized treatment regardless of supplementation with CoQ10 or placebo. There was no difference in headache outcomes between the CoQ10 and placebo groups at day 224. Due to the improvements seen in weeks 1-4, CoQ10 may lead to earlier improvement in headache severity, but given the sample size this conclusion warrants further investigation with a larger sample.
采用安慰剂对照、双盲、交叉、附加试验,评估辅酶 Q10(CoQ10)补充剂在预防儿童偏头痛中的疗效。
CoQ10 已被证明在预防成人偏头痛方面有效,但缺乏更严格方法学的儿科研究。在三级头痛中心就诊的大量儿童和青少年中发现 CoQ10 缺乏。CoQ10 有可能改变反复发作性偏头痛期间发生的炎症变化和线粒体功能的改变。因此,CoQ10 的缺乏可能会影响儿童和成人偏头痛的治疗反应和临床特征。
120 名偏头痛患儿和青少年被随机分为交叉、双盲、安慰剂对照、随机、附加研究,接受安慰剂或 CoQ10(100mg)补充剂治疗 224 天。在交叉点有 76 名患者的数据,50 名患者在终点进行了分析。评估治疗反应、整体头痛改善和头痛残疾。
安慰剂组和 CoQ10 组的偏头痛频率[F(1,60)=15.68,p<0.001]、严重程度[F(1,54)=8.09,p=0.006]和持续时间[F(1,45)=6.27,p=0.016]均随时间降低。从开始服用的 4 周内,CoQ10 治疗患者的频率从患者报告的基线开始显著改善。在偏头痛频率方面,治疗的前 4 周与最后 4 周之间没有组间差异[F(1,60)=2.34,p>0.05]、严重程度[F(1,54)=0.06,p>0.05]或持续时间[F(1,45)=0.14,p>0.05]。
总的来说,该研究结果表明,患有偏头痛的儿童和青少年随着多学科、标准化治疗的进行,无论是否补充 CoQ10 或安慰剂,都会随着时间的推移而改善。在第 224 天,CoQ10 组和安慰剂组之间的头痛结局没有差异。由于在第 1-4 周观察到的改善,CoQ10 可能导致头痛严重程度更早改善,但由于样本量较小,这一结论需要进一步用更大的样本进行研究。